PTIX Company Profile and Key Details

Protagenic Therapeutics, Inc. generated EPS of -$7.16 over the past year. Five-year average earnings growth is -10.56%. Protagenic Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 09, 2026, missed forecasts by -89.51%. The prior quarter beat by 150.0%. Over the last six quarters, Apple has recorded several small beats. These include 150.0% in November 16, 2021.

Protagenic Therapeutics, Inc. has 868.41 thousand shares outstanding. The public float is 491.61 thousand shares, elevated short interest at 5.61% of float. This equals 44.93 thousand shares. The short ratio is 0.01 days. Institutional investors hold 7.68% of the float. Insiders own 3.84%. Trinad Capital Master Fund Ltd. holds 3.12 million shares, KIER ISAAC has 1.79 million shares and MUSCI RAYMOND has 445.89 thousand shares.

PTIX has shown weak momentum, losing -58.05% over the past week and -81.0% over the past quarter, though year-to-date performance is down -51.92%. Short-term trend indicators are bullishly aligned (SMA20 -47.72%, SMA50 -61.53%, SMA200 -76.57%). The stock’s 14-day RSI is 25.3 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.82% below its high and over 5.41% above its low. Average 10-day trading volume of 6.54 thousand shares is significantly above the 3-month average of 3.96 thousand, indicating heightened recent market interest.

Protagenic Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.49. This means the shares are trading below this model’s fair value.

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) closed at $0.65 USD, gaining $0.22 (51.10%) from the previous close of $0.43. The stock is currently mid-range between its 52-week high and low $0.25 and $14.28. With a market capitalization of about $1.18 million, Protagenic Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.47). Key stats such as the average daily volume over the past year has been around 7.09 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Protagenic Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Garo H. Armen, the company employs approximately 1 people and listed since April 27, 2021. Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.

Protagenic Therapeutics, Inc. trades at a P/E ratio of -0.24, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.53 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.28, also above market averages.

Our AI price prediction model suggests that Protagenic Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.83%, with price expected at $0.56 by May 26, 2026, within a range of $0.40 to $0.72 3-Month Outlook: Projected fall of -72.3%, reaching $0.18 by August 10, 2026, with a range of $0.00 to $0.47. 1-Year Outlook: Projected loss of -81.54%, with price at $0.12 by May 12, 2027, within a range of $0.00 to $0.00.

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) shares are down -51.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Protagenic Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.24. Our AI forecast model points to short-term weakness (-13.83% over two weeks), a medium-term fall (-72.3% over three months), and a longer-term loss (-81.54% over one year), with expected trading ranges indicating moderate volatility.